a Department of Pathology and Laboratory Medicine , University of North Carolina at Chapel Hill Chapel Hill , NC , USA.
b Division of Cell Maintenance , Institute of Molecular Embryology and Genetics (IMEG) , Kumamoto University , Kumamoto , Japan.
Cell Cycle. 2018;17(7):833-843. doi: 10.1080/15384101.2018.1456296. Epub 2018 May 8.
Mutagenesis is a hallmark and enabling characteristic of cancer cells. The E3 ubiquitin ligase RAD18 and its downstream effectors, the 'Y-family' Trans-Lesion Synthesis (TLS) DNA polymerases, confer DNA damage tolerance at the expense of DNA replication fidelity. Thus, RAD18 and TLS polymerases are attractive candidate mediators of mutagenesis and carcinogenesis. The skin cancer-propensity disorder xeroderma pigmentosum-variant (XPV) is caused by defects in the Y-family DNA polymerase Pol eta (Polη). However it is unknown whether TLS dysfunction contributes more generally to other human cancers. Recent analyses of cancer genomes suggest that TLS polymerases generate many of the mutational signatures present in diverse cancers. Moreover biochemical studies suggest that the TLS pathway is often reprogrammed in cancer cells and that TLS facilitates tolerance of oncogene-induced DNA damage. Here we review recent evidence supporting widespread participation of RAD18 and the Y-family DNA polymerases in the different phases of multi-step carcinogenesis.
突变是癌细胞的一个标志和促进特征。E3 泛素连接酶 RAD18 及其下游效应物“Y 家族”跨损伤合成(TLS)DNA 聚合酶以牺牲 DNA 复制保真度为代价赋予了 DNA 损伤容忍性。因此,RAD18 和 TLS 聚合酶是诱变和癌变的有吸引力的候选介质。皮肤癌易感性疾病着色性干皮病变异型(XPV)是由 Y 家族 DNA 聚合酶 Pol eta(Polη)的缺陷引起的。然而,尚不清楚 TLS 功能障碍是否更普遍地导致其他人类癌症。最近对癌症基因组的分析表明,TLS 聚合酶产生了存在于多种癌症中的许多突变特征。此外,生化研究表明,TLS 途径在癌细胞中经常被重新编程,并且 TLS 有助于耐受致癌基因诱导的 DNA 损伤。在这里,我们回顾了最近的证据,这些证据支持 RAD18 和 Y 家族 DNA 聚合酶广泛参与多步骤致癌发生的不同阶段。